Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

VA launches psilocybin trial for veterans with treatment-resistant depression

5 August 2026 · By · Wire by Fusion42

Published

5 August 2026

Topic

opportunities

◆ Sectors

Mental Health

◆ Geography

United States

◆ Source

Read at legion.org →

◆ Verified

Fusion42 · 30 August 2026 · Fusion42 review

The U.S. Department of Veterans Affairs has launched a clinical trial named PIVOT to evaluate psilocybin's safety and effectiveness for veterans with treatment-resistant major depressive disorder, including those with PTSD, under FDA safety protocols.

This Wire brief sits within Fusion42's coverage of Mental Health.

◆ ◆ The Wire takeaway

You will find new research and market opportunities opening in psychedelic treatments for mental health veterans care as the VA advances psilocybin trials. Early moves in clinical trial participation and safety collaboration with the FDA could position you ahead in therapeutic offerings for hard-to-treat depression.

◆ Coverage

1 source · 5 Aug 2026

◆ Related on Wire

◆ Topics

Mental Healthpsilocybinclinical-trialveterans-healthmental-healthFDA-breakthrough